So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Pomalyst (pomalidomide) is a prescription drug that’s used to treat ... Pomalyst works to treat multiple myeloma in several ways: Pomalyst stops new cancer cells from forming by blocking the ...

The introduction of new ... drugs (IMiDs) and proteasome inhibitors has brought a major shift in therapeutic paradigm in the treatment of newly diagnosed and refractory multiple myeloma (MM).

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

Janssen has submitted a new combination regimen for its blockbuster multiple myeloma drug Darzalex for approval with the FDA and EMA, hoping to give the treatment another edge over emerging ...

With these goals and the development of new treatments, we hope to revolutionise care for all those living with multiple myeloma across the world and move closer to cures. Bain Capital has agreed ...

"The developers expect to create Russia's first drug for multiple myeloma based on CAR-NK therapy. It is planned that the drug using the new technology will pass all the necessary clinical trials and ...